Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.